Pharmaceutical companies' reluctance to take risks and make deals with small drug developers and biotech firms is stalling the pace of research-and-development partnerships, analysts said. Major acquisitions, such as the Pfizer-Wyeth merger, or smaller companies' reduced access to capital might be contributing to the situation, said Hari Kumar, chief business officer at Amira Pharmaceuticals.

Full Story:

Related Summaries